hyperpolarized helium-3 gas with MRI of the chest
DrugUsing hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
Other names: 3He hyperpolarized MRI
NCT Number: NCT02154568
Computer simulations are being developed to predict air flow abnormalities in the airways of patients with lung disease. The purpose of this study is to obtain actual gas flow measurements in the lungs of healthy patients and patients with lung disease and use these measurements to validate the computer models.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Snyder Translation Fontaine Research Center 480 Ray C. Hunt Drive, Charlottesville, Virginia, United States
The Biotechnology High Performance Computing Software Applications Institute (BHSAI) of the Department of Defense (DoD) is studying airflow in the lungs using computational fluid dynamics in order to characterize disease-specific airflow patterns and provide useful information for medical applications. To validate these models, they are seeking to obtain experimental data of airflow in human lungs, both healthy and diseased. An assessment of airflow can be obtained by using hyperpolarized noble gas (HNG) magnetic resonance imaging (MRI) or, more specifically, hyperpolarized helium-3 (HHe) MRI in conjunction with flow-encoding schemes that are well-established in conventional proton MRI
Four chronic obstructive pulmonary disease (COPD) patients and four healthy subjects will undergo pulmonary function tests (PFTs), computed tomography (CT) scan covering the mouth, neck, and chest, and hyperpolarized helium 3 MRI. Before and after the MRI scans, three spirometry readings will be taken while the subject is lying in the same position as in the MR scanners. Data will be analyzed by the BHSAI. UVa will provide the de-identified raw image data and the de-identified results of the spirometry and other tests to BHSAI
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
Other names: 3He hyperpolarized MRI
Time frame: Day 1
Using hyperpolarized helium as an inhaled contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
Time frame: Day1
Spirometry (FEV1)
Time frame: Day 1
Spirometry (FVC)
University of Virginia
Other
Flow Quantification in the Human Airways Using Hyperpolarized Helium 3 MRI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05930158
COPD, Chronic Disease
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06505902
COPD, Chronic Disease
Copenhagen, København Ø, Denmark
View Trial DetailsNCT05962645
COPD, Chronic Disease
Miami, Florida, United States
View Trial DetailsNCT06135701
COPD, Chronic Disease
Copenhagen, København Ø, Denmark
View Trial Details